SecBot SecBot
SECBOTREPLAY Home › Report › ARMP

ARMP · Armata Pharmaceuticals announced FDA Breakthrough Therapy designation…

Armata Pharmaceuticals, Inc. · 8-K filed Sep 14, 2026 at 07:12 ET

At the news

BULLISHIMPACT 7/10

8-K filed Sep 14, 2026 at 07:12 ET

Armata Pharmaceuticals announced FDA Breakthrough Therapy designation for AP-SA02, its intravenous phage therapy for complicated Staphylococcus aureus bacteremia (including MRSA). The designation is supported by Phase 1b/2a data showing 100% of AP-SA02 patients maintained clinical response at 28 days vs. 75% for placebo, and provides expedited FDA review, cross-disciplinary collaboration, and senior management engagement. This is a significant regulatory milestone that de-risks the Phase 3 program and enhances the asset's value, though the company remains pre-revenue with no financial data in this filing.

  • FDA granted Breakthrough Therapy designation to AP-SA02 for adjunct treatment of complicated S. aureus bacteremia (MSSA and MRSA)
  • Phase 1b/2a diSArm study: 100% of AP-SA02 patients maintained clinical response at 28 days vs. 75% for placebo
  • AP-SA02 now holds Breakthrough Therapy, Fast Track, and QIDP designations
  • Phase 3 superiority study anticipated to initiate in second half of 2026

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access